These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

794 related items for PubMed ID: 28293106

  • 1. Inhaled treatment of COPD: a Delphi consensus statement.
    Ninane V, Corhay JL, Germonpré P, Janssens W, Joos GF, Liistro G, Vincken W, Gurdain S, Vanvlasselaer E, Lehouck A.
    Int J Chron Obstruct Pulmon Dis; 2017; 12():793-801. PubMed ID: 28293106
    [Abstract] [Full Text] [Related]

  • 2. LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.
    Rodrigo GJ, Price D, Anzueto A, Singh D, Altman P, Bader G, Patalano F, Fogel R, Kostikas K.
    Int J Chron Obstruct Pulmon Dis; 2017; 12():907-922. PubMed ID: 28360514
    [Abstract] [Full Text] [Related]

  • 3. Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis.
    Hurst JR, Dilleen M, Morris K, Hills S, Emir B, Jones R.
    Int J Chron Obstruct Pulmon Dis; 2018; 13():781-792. PubMed ID: 29551894
    [Abstract] [Full Text] [Related]

  • 4. Comparative Effectiveness of Long-Acting Beta2 -Agonist Combined with a Long-Acting Muscarinic Antagonist or Inhaled Corticosteroid in Chronic Obstructive Pulmonary Disease.
    Samp JC, Joo MJ, Schumock GT, Calip GS, Pickard AS, Lee TA.
    Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
    [Abstract] [Full Text] [Related]

  • 5. Long-acting muscarinic antagonist (LAMA) plus long-acting beta-agonist (LABA) versus LABA plus inhaled corticosteroid (ICS) for stable chronic obstructive pulmonary disease (COPD).
    Horita N, Goto A, Shibata Y, Ota E, Nakashima K, Nagai K, Kaneko T.
    Cochrane Database Syst Rev; 2017 Feb 10; 2(2):CD012066. PubMed ID: 28185242
    [Abstract] [Full Text] [Related]

  • 6. Maintenance therapy in COPD: time to phase out ICS and switch to the new LAMA/LABA inhalers?
    Tariq SM, Thomas EC.
    Int J Chron Obstruct Pulmon Dis; 2017 Feb 10; 12():1877-1882. PubMed ID: 28694698
    [Abstract] [Full Text] [Related]

  • 7. Respiratory medication used in COPD patients from seven Latin American countries: the LASSYC study.
    Casas A, Montes de Oca M, Menezes AM, Wehrmeister FC, Lopez Varela MV, Mendoza L, Ramírez L, Miravitlles M.
    Int J Chron Obstruct Pulmon Dis; 2018 Feb 10; 13():1545-1556. PubMed ID: 29785104
    [Abstract] [Full Text] [Related]

  • 8. LAMA/LABA vs ICS/LABA in the treatment of COPD in Japan based on the disease phenotypes.
    Hizawa N.
    Int J Chron Obstruct Pulmon Dis; 2015 Feb 10; 10():1093-102. PubMed ID: 26089659
    [Abstract] [Full Text] [Related]

  • 9. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.
    Mapel D, Laliberté F, Roberts MH, Sama SR, Sundaresan D, Pilon D, Lefebvre P, Duh MS, Patel J.
    Int J Chron Obstruct Pulmon Dis; 2017 Feb 10; 12():1825-1836. PubMed ID: 28684905
    [Abstract] [Full Text] [Related]

  • 10. Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal.
    Vanfleteren L, Fabbri LM, Papi A, Petruzzelli S, Celli B.
    Int J Chron Obstruct Pulmon Dis; 2018 Feb 10; 13():3971-3981. PubMed ID: 30587953
    [Abstract] [Full Text] [Related]

  • 11. Long-acting muscarinic antagonist and long-acting β2-agonist combination for the treatment of maintenance therapy-naïve patients with chronic obstructive pulmonary disease: a narrative review.
    Buhl R, Miravitlles M, Anzueto A, Brunton S.
    Ther Adv Respir Dis; 2024 Feb 10; 18():17534666241279115. PubMed ID: 39352722
    [Abstract] [Full Text] [Related]

  • 12. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
    Zhong N, Wang C, Zhou X, Zhang N, Humphries M, Wang L, Thach C, Patalano F, Banerji D, LANTERN Investigators.
    Int J Chron Obstruct Pulmon Dis; 2015 Feb 10; 10():1015-26. PubMed ID: 26082625
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial.
    Vogelmeier CF, Gaga M, Aalamian-Mattheis M, Greulich T, Marin JM, Castellani W, Ninane V, Lane S, Nunez X, Patalano F, Clemens A, Kostikas K, CRYSTAL study investigators.
    Respir Res; 2017 Jul 18; 18(1):140. PubMed ID: 28720132
    [Abstract] [Full Text] [Related]

  • 14. Overuse of long-acting β2-agonist/inhaled corticosteroids in patients with chronic obstructive pulmonary disease: time to rethink prescribing patterns.
    Brunton SA, Hogarth DK.
    Postgrad Med; 2023 Nov 18; 135(8):784-802. PubMed ID: 38032494
    [Abstract] [Full Text] [Related]

  • 15. Role of Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist Therapy in Chronic Obstructive Pulmonary Disease.
    Petite SE.
    Ann Pharmacother; 2017 Aug 18; 51(8):696-705. PubMed ID: 28410560
    [Abstract] [Full Text] [Related]

  • 16. Current evidence for COPD management with dual long-acting muscarinic antagonist/long-acting β2-agonist bronchodilators.
    Skolnik NS, Nguyen TS, Shrestha A, Ray R, Corbridge TC, Brunton SA.
    Postgrad Med; 2020 Mar 18; 132(2):198-205. PubMed ID: 31900019
    [Abstract] [Full Text] [Related]

  • 17. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design.
    Rennard SI, Martinez FJ, Rabe KF, Sethi S, Pizzichini E, McIvor A, Siddiqui S, Anzueto A, Zhu H.
    Int J Chron Obstruct Pulmon Dis; 2016 Mar 18; 11():1921-8. PubMed ID: 27574416
    [Abstract] [Full Text] [Related]

  • 18. Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study.
    Greulich T, Kostikas K, Gaga M, Aalamian-Mattheis M, Lossi NS, Patalano F, Nunez X, Pagano VA, Fogel R, Vogelmeier CF, Clemens A.
    Int J Chron Obstruct Pulmon Dis; 2018 Mar 18; 13():1229-1237. PubMed ID: 29713156
    [Abstract] [Full Text] [Related]

  • 19. Double bronchodilation in chronic obstructive pulmonary disease: a crude analysis from a systematic review.
    Lopez-Campos JL, Calero-Acuña C, Márquez-Martín E, Quintana Gallego E, Carrasco-Hernández L, Abad Arranz M, Ortega Ruiz F.
    Int J Chron Obstruct Pulmon Dis; 2017 Mar 18; 12():1867-1876. PubMed ID: 28694697
    [Abstract] [Full Text] [Related]

  • 20. Single-inhaler triple therapy in patients with chronic obstructive pulmonary disease: a systematic review.
    Langham S, Lewis J, Pooley N, Embleton N, Langham J, Han MK, Chalmers JD.
    Respir Res; 2019 Nov 04; 20(1):242. PubMed ID: 31684965
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 40.